1Scaravaglio P,Guglielmelli T.Giugliano, et al. Detection of minimal residual disease in peripheral blood stem cells from two acute myeloid leukemia patients with trisomy 8 predicts early relapse alter autologous bone marrow transplantation [J], Cancer Genet Cytogenet, 2002,133 : 98 -- 101.
2Mancini M,Cedrone M, Diverio D,et al. Use of dual-color interphase FISH for the detection of inv(16) in acute myeloid leukemia at diagnosis, relapse and during follow-upz a study of 23 patients [J]. Leukemia, 2000,14 : 364- 368.
3Radich J P. The use oi PCR technology for detecting minimal residual disease in patients with leukemia [J]. Rev Immunogenet, 1999,1 : 265 - 278.
4Picherr G.Roy D C.Gonin R.a el. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneii: bone marrow transplantation for chronic myelogenous leukemia[J]. J Clin Ontology, 1995, 13 :1704-- 1713.
5Lin F,Van Rhee F,Goldman J M,et al. Kinetics of increasing bcr/abl transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation [J]. Biood, 1996, 87:4473--4478.
6Wasserman R, Galili N, ho Y,et al. Residual disease at the end of induetion therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia[J]. J Clin Oncoloay, 1989, 10 : 1879-1888.
7Cave H,Ten Bosch J W,Suciu S,et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of CancerChildhood Leukemia Cooperative Group[J]. New Engl J Med. 1998, 339:591 -598.
8Miller W H,Levine K,Deblasio A,et al. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-alpha fusion mRNA[J]. Blood, 1993,82 : 1689-- 1694.
9Guerrasio A,Pilatrino C,De Mieheli D, et al. Assessment of minimal residual disease (MRD) in CBFbeta/MYH11positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts [J]. Leukemia, 2002,16 : 1176-- 1181.
10Tamaki H, Ogawa H, Ohyashiki K, et al The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes [J]. Leukemia, 1999, 13:393 -399.
5Darrell C. Keenneth A. Recent advanccs in flow cytomelry: application to the diagnosis of hemaloligic malignancy [J]. Blood,1997,90(8) :2863-2892.
6Kern W, Haferlach C, Haferlach T, et al. Monitoring of minimal residual disease in acute myeloid leukemia[J]. Cancer, 2008,112(1) :4-16.
7Carow C E. Levenstein M, Kaufmann S H, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK1/STK2) in human leulemias[J]. Blood,1996,87(3):1089-1096.
8Ikeda H, Lethe B, Lehman F, et al. Characterization of an antigen thai is recognized on a melanoma showing partial HLA loss CTL expressing an NK inhibitory receptor[J]. Immunity, 1997,11(6):199-208.
9Matsushita M, Ikeda H, Kizaki M, et al. Quantitative monitoring of the PRAME gene for the detection ot minimal residual disease in leukemia[J]. Br J Haematol,2001,3(4): 916-926.
10Spanaki A, Perdikogianni C, Linardakis E, et al. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia[J]. Leuk Res,2007,31(5):639-642.
